Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer

Dezheng Huo; Francis Ikpatt; Andrey Khramtsov; Jean-Marie Dangou; Rita Nanda; James Dignam; Bifeng Zhang; Tatyana Grushko; Chunling Zhang; Olayiwola Oluwasola; David Malaka; Sani Malami; Abayomi Odetunde; Adewumi O Adeoye; Festus Iyare; Adeyinka Falusi; Charles M Perou; Olufunmilayo I Olopade

doi:10.1200/JCO.2008.19.6873

Back

Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer

Journal article

Open access

Peer reviewed

Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer

Dezheng Huo, Francis Ikpatt, Andrey Khramtsov, Jean-Marie Dangou, Rita Nanda, James Dignam, Bifeng Zhang, Tatyana Grushko, Chunling Zhang, Olayiwola Oluwasola, …

Journal of clinical oncology, Vol.27(27), pp.4515-4521

2009-09-20

DOI: https://doi.org/10.1200/JCO.2008.19.6873

PMCID: PMC2754904

PMID: 19704069

Abstract

Purpose Compared with white women, black women experience a disproportionate burden of aggressive breast cancer for reasons that remain unknown and understudied. In the first study of its kind, we determined the distribution of molecular subtypes of invasive breast tumors in indigenous black women in West Africa. Patients and Methods The study comprised 507 patients diagnosed with breast cancer between 1996 and 2007 at six geographic regions in Nigeria and Senegal. Formalin-fixed and paraffin-embedded sections were constructed into tissue microarrays and immunostained with 15 antibodies. Five molecular subtypes were determined, and hierarchical cluster analysis was conducted to explore subgroups for unclassified cases. Results The mean (± standard deviation) age of 378 patients in the first cohort was 44.8 ± 11.8 years, with the majority of women presenting with large (4.4 ± 2.0 cm) high-grade tumors (83%) in advanced stages (72% node positive). The proportions of estrogen receptor (ER) –positive, progesterone receptor–positive, and human epidermal growth factor receptor 2 (HER2) –positive tumors were 24%, 20%, and 17%, respectively. Triple negativity for these markers was predominant, including basal-like (27%) and unclassified subtype (28%). Other subtypes were luminal A (27%), luminal B (2%), and HER2 positive/ER negative (15%). The findings were replicated in the second cohort of 129 patients. The unclassified cases could be grouped into a bad prognosis branch, with expression of vascular endothelial growth factor, B-cell lymphoma extra-large protein, and Cyclin E, and a good prognosis branch, with expression of B-cell lymphoma protein 2 and Cyclin D1. Conclusion These findings underscore the urgent need for research into the etiology and treatment of the aggressive molecular subtypes that disproportionately affect young women in the African diaspora.

Files and links (1)

url

https://doi.org/10.1200/JCO.2008.19.6873View

Published (Version of record) Open

Metrics

7 Record Views

268 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.119 Breast Cancer Scanning; 1.119.454 Breast Cancer Incidence
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer
Creators: Dezheng Huo - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Francis Ikpatt - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Andrey Khramtsov - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Jean-Marie Dangou - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Rita Nanda - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
James Dignam - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Bifeng Zhang - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Tatyana Grushko - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Chunling Zhang - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Olayiwola Oluwasola - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
David Malaka - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Sani Malami - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Abayomi Odetunde - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Adewumi O Adeoye - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Festus Iyare - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Adeyinka Falusi - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Charles M Perou - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Olufunmilayo I Olopade - From the Department of Health Studies, and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; Institut Pasteur, Dakar, Sénégal; University of Ibadan, Ibadan; Usman Danfodio University Teaching Hospital, Sokoto; Ebonyi State University Teaching Hospital, Abakaliki, Nigeria; and University of North Carolina, Chapel Hill, NC
Publication Details: Journal of clinical oncology, Vol.27(27), pp.4515-4521
Language: English
Resource Type: Journal article
PMID: 19704069
PMCID: PMC2754904
Record Identifier: 991031614253402976